CR11266A - Derivados de pirrolidin-2ona como moduladores del receptor de androgeno - Google Patents

Derivados de pirrolidin-2ona como moduladores del receptor de androgeno

Info

Publication number
CR11266A
CR11266A CR11266A CR11266A CR11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A
Authority
CR
Costa Rica
Prior art keywords
2ona
pirrolidin
derivatives
receiver modulators
androgen
Prior art date
Application number
CR11266A
Other languages
English (en)
Spanish (es)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11266A publication Critical patent/CR11266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR11266A 2007-08-07 2010-02-12 Derivados de pirrolidin-2ona como moduladores del receptor de androgeno CR11266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19

Publications (1)

Publication Number Publication Date
CR11266A true CR11266A (es) 2010-03-22

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11266A CR11266A (es) 2007-08-07 2010-02-12 Derivados de pirrolidin-2ona como moduladores del receptor de androgeno

Country Status (34)

Country Link
US (2) US8420694B2 (enExample)
EP (1) EP2176220B1 (enExample)
JP (1) JP5292390B2 (enExample)
KR (1) KR20100049644A (enExample)
CN (1) CN101821235B (enExample)
AR (1) AR067823A1 (enExample)
AU (1) AU2008284662B2 (enExample)
BR (1) BRPI0814957B8 (enExample)
CA (1) CA2695852C (enExample)
CL (1) CL2008002313A1 (enExample)
CO (1) CO6160326A2 (enExample)
CR (1) CR11266A (enExample)
CY (1) CY1114067T1 (enExample)
DK (1) DK2176220T3 (enExample)
DO (1) DOP2010000053A (enExample)
EA (1) EA017429B1 (enExample)
ES (1) ES2406685T3 (enExample)
GE (1) GEP20125571B (enExample)
HR (1) HRP20130374T1 (enExample)
JO (1) JO2864B1 (enExample)
MA (1) MA31639B1 (enExample)
ME (1) ME01579B (enExample)
MX (1) MX2010001484A (enExample)
MY (1) MY159910A (enExample)
NZ (1) NZ583624A (enExample)
PE (1) PE20090899A1 (enExample)
PL (1) PL2176220T3 (enExample)
PT (1) PT2176220E (enExample)
RS (1) RS52812B (enExample)
SI (1) SI2176220T1 (enExample)
TN (1) TN2010000062A1 (enExample)
TW (1) TWI418543B (enExample)
WO (1) WO2009020234A2 (enExample)
ZA (1) ZA201001289B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017429B1 (ru) * 2007-08-07 2012-12-28 Такеда Фармасьютикал Компани Лимитед Циклические аминные соединения
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
AR071069A1 (es) * 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (en) * 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP2834216A1 (en) * 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
EP3378472A1 (en) * 2012-08-09 2018-09-26 Dynamis Therapeutics, Inc. Combinations of meglumine
US9868905B2 (en) 2012-09-21 2018-01-16 Merck Patent Gmbh Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
CN113382990B (zh) 2019-01-11 2024-11-19 格吕伦塔尔有限公司 取代的吡咯烷酰胺iii
MA54946A (fr) 2019-02-12 2021-12-22 Radius Pharmaceuticals Inc Procédés et composés
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
DE69938005T2 (de) * 1998-09-22 2009-01-15 Astellas Pharma Inc. Cyanophenyl-derivate
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
EP2289503B1 (en) 2001-12-06 2016-06-29 University of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
EP1466902A4 (en) * 2001-12-28 2005-11-09 Takeda Pharmaceutical ANTAGONISTS OF THE ANDROGEN RECEPTOR
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US7649001B2 (en) 2002-08-12 2010-01-19 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1747193A1 (en) * 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
ZA200610270B (en) 2004-05-17 2008-06-25 Acadia Pharm Inc Androgen receptor modulators and method of treating disease using the same
GEP20094851B (en) 2004-06-07 2009-12-10 The Univ Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
JP5203712B2 (ja) 2005-01-10 2013-06-05 アカディア ファーマシューティカルズ インコーポレイテッド 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PT1891038E (pt) 2005-05-13 2008-12-02 Lilly Co Eli N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio
CA2617256C (en) * 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
US20090042857A1 (en) * 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
MX2009000715A (es) 2006-07-19 2009-07-22 Osurf Ohio State University Re Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
RU2009106214A (ru) 2006-07-26 2010-09-10 Новартис АГ (CH) Ингибиторы ундекапренилпирофосфатсинтазы
JP5241507B2 (ja) 2006-11-30 2013-07-17 武田薬品工業株式会社 環状アミン化合物
EA017429B1 (ru) * 2007-08-07 2012-12-28 Такеда Фармасьютикал Компани Лимитед Циклические аминные соединения

Also Published As

Publication number Publication date
NZ583624A (en) 2012-06-29
ES2406685T3 (es) 2013-06-07
BRPI0814957A2 (pt) 2015-02-03
EA201070246A1 (ru) 2010-08-30
CN101821235B (zh) 2012-11-14
MY159910A (en) 2017-02-15
ZA201001289B (en) 2011-04-28
MA31639B1 (fr) 2010-08-02
CL2008002313A1 (es) 2009-05-15
US8420694B2 (en) 2013-04-16
DOP2010000053A (es) 2010-07-15
CN101821235A (zh) 2010-09-01
AR067823A1 (es) 2009-10-21
MX2010001484A (es) 2010-03-04
EP2176220A2 (en) 2010-04-21
JP2010535704A (ja) 2010-11-25
CY1114067T1 (el) 2016-07-27
TN2010000062A1 (en) 2011-09-26
WO2009020234A3 (en) 2009-04-16
TWI418543B (zh) 2013-12-11
RS52812B (sr) 2013-10-31
PE20090899A1 (es) 2009-08-06
CA2695852A1 (en) 2009-02-12
HK1143972A1 (en) 2011-01-21
AU2008284662B2 (en) 2013-07-25
JP5292390B2 (ja) 2013-09-18
SI2176220T1 (sl) 2013-05-31
KR20100049644A (ko) 2010-05-12
CA2695852C (en) 2017-01-03
US20090042967A1 (en) 2009-02-12
DK2176220T3 (da) 2013-06-10
PT2176220E (pt) 2013-04-09
EP2176220B1 (en) 2013-03-27
CO6160326A2 (es) 2010-05-20
PL2176220T3 (pl) 2013-08-30
BRPI0814957B1 (pt) 2019-12-03
TW200916439A (en) 2009-04-16
JO2864B1 (en) 2015-03-15
WO2009020234A2 (en) 2009-02-12
EA017429B1 (ru) 2012-12-28
BRPI0814957B8 (pt) 2021-05-25
HRP20130374T1 (en) 2013-05-31
AU2008284662A1 (en) 2009-02-12
US7834051B2 (en) 2010-11-16
GEP20125571B (en) 2012-07-10
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
UY32469A (es) Composiciones y metodos para modular la senda de señalizacion de wnt
UA107791C2 (en) Pesticidal compositions
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
AU2011232516A8 (en) Chemical compounds
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
BR112017006253A2 (pt) novos compostos
CR20110268A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
UY31688A1 (es) Plaguicidas
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
CR20110474A (es) Derivados de benzofurano
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
IN2012DN02876A (enExample)
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
CO6491037A2 (es) Derivados de pirazinooxazepina
AR103355A1 (es) Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística